Synthesis of sulfaphenazole derivatives and their use as inhibitors and tools for comparing the active sites of human liver cytochromes P450 of the 2C subfamily

Citation
Nt. Ha-duong et al., Synthesis of sulfaphenazole derivatives and their use as inhibitors and tools for comparing the active sites of human liver cytochromes P450 of the 2C subfamily, J MED CHEM, 44(22), 2001, pp. 3622-3631
Citations number
37
Categorie Soggetti
Chemistry & Analysis
Journal title
JOURNAL OF MEDICINAL CHEMISTRY
ISSN journal
00222623 → ACNP
Volume
44
Issue
22
Year of publication
2001
Pages
3622 - 3631
Database
ISI
SICI code
0022-2623(20011025)44:22<3622:SOSDAT>2.0.ZU;2-X
Abstract
Twenty-three new derivatives of sulfaphenazole (SPA) were synthesized to fu rther explore the topology of the active sites of human liver cytochromes P 450 of the 2C subfamily and to find new selective inhibitors of these cytoc hromes. These compounds are derived from SPA by replacement of the NH2 and H (of the SO2NH function) substituents of SPA with various R-1 and R-2 grou ps, respectively. Their inhibitory effects were studied on recombinant CYP 2C8, 2C9, 2C18, and 2C19 expressed in yeast. High affinities for CYP 2C9 (I C50 < 1 muM) were only observed for SPA derivatives having the SO2NH functi on and a relatively small R-1 substituent (R-1 = NH2, CH3). Any increase in the size of R-1 led to a moderate decrease of the affinity, and the N-alky lation of the SO2NH function of SPA to a greater decrease of this affinity. The same structural changes led to opposite effects on molecular recogniti on by CYP 2C8 and 2C18, which generally exhibited similar behaviors. Thus, contrary to CYP 2C9, CYP 2C8 and 2C18 generally prefer neutral compounds wi th relatively large R-1 and R2 substituents. CYP 2C19 showed an even lower affinity for anionic compounds than CYP 2C8 and 2C18. However, as CYP 2C8 a nd 2C18, CYP 2C19 showed a much better affinity for neutral compounds deriv ed ftom N-alkylation of SPA and for anionic compounds bearing a larger R, s ubstituent. One of the new compounds (R-1 = methyl, R-2 = propyl) inhibited all human CYP 2Cs with IC50 values between 10 and 20 muM, while another on e (R-1 = allyl, R-2 = methyl) inhibited all CYP 2Cs except CYP 2C9, and a t hird one (R-1 = R-2 = methyl) inhibited all CYP 2Cs except CYP 2C8. Only 2 compounds of the 25 tested derivatives were highly selective toward one hum an CYP 2C; these are SPA and compound I (Ri = CH3, R2 = H), which acted as selective CYP 2C9 inhibitors. However, some SPA derivatives selectively inh ibited CYP 2C8 and 2C18. Since CYP 2C18 is hardly detectable in human liver , these derivatives could be interesting molecules to selectively inhibit C YP 2C8 in human liver microsomes. Thus, compound 11 (R-1 = NH2, R-2 = (CH2) (2)CH(CH3)(2)) appears to be particularly interesting for that purpose as i ts IC50 value for CYP 2C8 is low (3 muM) and 20-fold smaller than those fou nd for CYP 2C9 and 2C19.